Physician profile
David Hahn
NPI 1912926353
$1,008.65
in general payments reported to CMS, 2019-2025
12 companies · $164 in 2025
The $164 reported for 2025 was less than what a typical Vascular & Interventional Radiology provider received nationally (typical 2025 total: $537).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $590 · 2022: $24.96 · 2024: $230 · 2025: $164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $394.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $393.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $236.47 | 2021 | |
| Angiodynamics, INC. | $166.68 | 2021-2022 | |
| Veryan Medical Incorporated | $145.23 | 2024 | Biomimics 3d Vascular Stent System |
| Sirtex Medical INC | $125.88 | 2025 | Sir-Spheres Microspheres |
| Innova Vascular INC. | $84.68 | 2024 | |
| Medtronic, INC. | $79.16 | 2021 | |
| Terumo Medical Corporation | $78.92 | 2021 | |
| Cook Medical LLC | $23.08 | 2021 | |
| Abk Biomedical USA, INC. | $21.35 | 2025 | Eye90 Microspheres |
| Avinger INC. | $18.63 | 2021 | |
| Janssen Pharmaceuticals, INC | $16.72 | 2025 | Uptravi |
| Penumbra, INC. | $11.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Hahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.